• Wondering whether COMPASS Pathways at around US$9.15 still stacks up on value or has run ahead of itself? This article breaks down what the recent moves might mean for you as an investor.
• The stock has recently shown strong momentum, with returns of 37.4% over 7 days, 75.3% over 30 days, 39.7% year to date and 129.3% over 1 year, while the 3 year return sits at 13.2% and the 5 year return at a loss of 76.5%.
• These swings have come as COMPASS Pathways continues to sit in the spotlight of investor interest, with sentiment and expectations playing a key role in how the share price moves. For a company in this space, changes in market attention, funding conditions and sector focus often feed directly into short term price reactions.
• Even with all this volatility, COMPASS Pathways currently carries a valuation score of 2 out of 6. Next, you will see how different valuation methods assess the stock today and then, at the end of the article, a broader framework to help you judge its value more clearly.

COMPASS Pathways scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: COMPASS Pathways Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business might be worth today by projecting its future cash flows and then discounting those back into present value terms.

For COMPASS Pathways, the latest twelve month Free Cash Flow (FCF) is a loss of about US$157.24 million. Analysts provide cash flow estimates out to 2030, and Simply Wall St extends these into a 2 Stage Free Cash Flow to Equity model, with projections running through to 2035. Within this, FCF is forecast to move from losses in the near term to a projected positive FCF of about US$326.66 million in 2030, with later years extrapolated by the model rather than by analysts.

Putting these projected cash flows together, the DCF model arrives at an estimated intrinsic value of roughly US$175.60 per share. Compared with the recent share price around US$9.15, this implies the stock is about 94.8% below that modelled value, which indicates a very wide gap between the cash flow based estimate and where the market is currently pricing the shares.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests COMPASS Pathways is undervalued by 94.8%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

Approach 2: COMPASS Pathways Price vs Book

P/B is often used to value companies where earnings are not yet meaningful, because it compares the share price with the accounting value of net assets on the balance sheet. For profitable, steady businesses, investors usually accept a higher P/B when they expect stronger growth and lower risk, and a lower P/B when prospects are more uncertain.

COMPASS Pathways currently trades on a P/B of about 23.36x, while the broader Biotechs industry sits around 2.39x and the peer group average is about 5.89x. This highlights a wide gap between COMPASS Pathways and both its sector and closer peers on this metric.

Simply Wall St’s Fair Ratio is a proprietary estimate of what a more suitable P/B might be after factoring in elements such as earnings growth, profit margins, risk profile, market cap and the industry context. This tailored approach can be more informative than a simple peer or industry comparison because it adjusts for company specific features rather than assuming one size fits all. Comparing COMPASS Pathways’ current P/B of 23.36x with its Fair Ratio suggests the shares are trading meaningfully above that tailored benchmark.

Result: OVERVALUED

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your COMPASS Pathways Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as simple stories you create about COMPASS Pathways that link your view of its trials, regulatory path and commercial roll out to specific assumptions for future revenue, earnings and margins, and then to a Fair Value that you can compare with the current price to help inform whether to buy, hold or sell. All of this is available within an easy tool on Simply Wall St’s Community page that updates automatically when new news or earnings arrive. For example, one COMPASS Pathways Narrative might align with the bullish Fair Value of about US$52.55 or even the US$70 upper analyst target, while another might sit closer to the cautious US$8 view. By seeing those stories side by side, you can choose which one best fits your expectations and risk tolerance.

For COMPASS Pathways, however, we will make it really easy for you with previews of two leading COMPASS Pathways Narratives:

Fair Value: US$52.55

Implied undervaluation vs latest close: about 82.6% below this Fair Value

Revenue growth assumption to 2029: very large, reflecting a step up from zero revenue

• Assumes COMP360 moves through Phase III, secures FDA approval and is rolled out across thousands of interventional psychiatry sites, with treatment resistant depression at the core and PTSD as a second major indication.
• Builds on bullish analyst forecasts that COMPASS Pathways scales to US$670.7 million in revenue and US$242.9 million in earnings by around April 2029, with a 36.2% profit margin and a P/E of 42.6x on those earnings.
• Accepts higher execution and regulatory risk in exchange for a larger end market and higher profitability, using a 7.6% discount rate to arrive at a Fair Value of US$52.55 per share.

Fair Value: US$8.00

Implied overvaluation vs latest close: about 14.4% above this Fair Value

Revenue growth assumption to 2029: very large, but off a much smaller base and at lower earnings than bullish scenarios

• Assumes COMP360 still progresses, but revenue only reaches US$59.5 million by around March 2029, with profitability aligning with the wider US Biotechs industry margin of 10.9% rather than materially higher levels.
• Requires a high 159.5x P/E on the projected US$6.5 million in earnings to justify the US$8.00 target, while also factoring in share count growth of 2.62% per year and use of a 7.6% discount rate.
• Focuses on risks around trial outcomes, regulatory conditions, slower adoption at treatment centers and potential dilution from future funding, which together keep the Fair Value closer to the low end of analyst targets.

Once you have a sense of which of these stories feels closer to your expectations for trials, regulation and commercial uptake, you can use the full set of COMPASS Pathways Narratives to fine tune your own view of what the stock is worth today. See what the community is saying about COMPASS Pathways

Do you think there's more to the story for COMPASS Pathways? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.